icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
FROM COMBINATION-THERAPY TO MONO-THERAPY IN TREATMENT EXPERIENCED CHB PATIENTS WITH VIRAL RISISTENCE OR PARTIAL RESPONSES: FIRST RESULTS OF AN INTERNATIONAL MULTICENTER COHORT STUDY
 
 
  Download the PDF here
 
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
 
J. Petersen1, S. Unger1, M. Buti2, M.Lutgehetmann3, P. Lampertico4, C. Sarrazin5, P. Buggisch11 IFI Institute for Interdisciplinary Medicine, Asklepios Klinik St. Georg Hamburg, Germany, Germany, 2 Department of Hepatology, Hospital Vall de Hebron, Barcelona, Spain, 3 Microbiology and Medicine, University Hospital Hamburg Eppendorf, Hamburg, Germany, 4 Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital Milan, Italy, 5 Medicine, University of Frankfurt, Germany
 
Discussion: Mono-therapy with ETV or TDF after successful rescue combination therapy with ETV plus TDF in CHB patients harboring viral resistance patterns or showing only partial virologic responses to previous therapies was efficient, safe and well tolerated in patients with or without advanced liver disease.

EASL1.gif

EASL2.gif

EASL3.gif